Akorn-Strides joint venture enters buy agreement with Pfizer for ANDAs Akorn.

Akorn-Strides joint venture enters buy agreement with Pfizer for ANDAs Akorn, Inc. , a niche generic pharmaceutical organization, today reported that its Akorn-Strides LLC jv has entered into a purchase contract with Pfizer Inc. To market 16 Abbreviated New Medication Approvals and 6 filed ANDAs generic sildenafil . For its portion, Akorn, Inc. Will receive $35 million in money. Until April 30 Akorn-Strides LLC will continue steadily to manufacture and distribute the approved products, 2011. September 30 In the three quarters finished, 2010, Akorn recognized $1.9 million in revenue and around $2.0 million in altered EBITDA as a result of its participation in the Akorn-Strides LLC joint venture.